{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:38:42Z","timestamp":1787647122196,"version":"build-2736575974"},"reference-count":81,"publisher":"Frontiers Media SA","funder":[{"DOI":"10.13039\/501100002702","name":"Aalborg Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002702","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006304","name":"Aalborg Universitetshospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006304","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"DOI":"10.3389\/fendo.2017.00079","type":"journal-article","created":{"date-parts":[[2017,4,24]],"date-time":"2017-04-24T10:03:53Z","timestamp":1493028233000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":40,"title":["Contemporary Medical Management of Primary Hyperparathyroidism: A Systematic Review"],"prefix":"10.3389","volume":"8","author":[{"given":"Julius Simoni","family":"Leere","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper","family":"Karmisholt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Robaczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Vestergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2017,4,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.1210\/jc.2014-1413","article-title":"Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop","volume":"99","author":"Bilezikian","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S8756-3282(97)00078-1","article-title":"Primary hyperparathyroidism: biochemical markers and bone mineral density at multiple skeletal sites in Danish patients","volume":"21","author":"Christiansen","year":"1997","journal-title":"Bone"},{"key":"B3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1046\/j.1365-2796.1998.00241.x","article-title":"Increased biochemical markers of bone formation and resorption in primary hyperparathyroidism with special reference to patients with mild disease","volume":"243","author":"Valdemarsson","year":"1998","journal-title":"J Intern Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1210\/jc.2007-1215","article-title":"The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years","volume":"93","author":"Rubin","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1056\/NEJM199910213411701","article-title":"A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery","volume":"341","author":"Silverberg","year":"1999","journal-title":"N Engl J Med"},{"key":"B6","first-page":"18","article-title":"Prospective 10-year study of postmenopausal women with asymptomatic primary hyperparathyroidism","volume":"121","author":"Bolland","year":"2008","journal-title":"N Z Med J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/8756-3282(92)90207-D","article-title":"Comparison of low-dose intramuscular and intravenous salcatonin in the treatment of primary hyperparathyroidism","volume":"13","author":"Stone","year":"1992","journal-title":"Bone"},{"key":"B8","doi-asserted-by":"publisher","first-page":"S131","DOI":"10.1002\/jbmr.5650061427","article-title":"Medical management of asymptomatic primary hyperparathyroidism","volume":"6","author":"Shane","year":"1991","journal-title":"J Bone Miner Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00223-012-9659-5","article-title":"Effects of strontium ranelate administration on calcium metabolism in female patients with postmenopausal osteoporosis and primary hyperparathyroidism","volume":"92","author":"Carnevale","year":"2013","journal-title":"Calcif Tissue Int"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/bjs.1800810819","article-title":"Somatostatin and primary hyperparathyroidism","volume":"81","author":"Lucarotti","year":"1994","journal-title":"Br J Surg"},{"key":"B11","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1111\/j.1365-2265.2008.03301.x","article-title":"Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients","volume":"69","author":"Faggiano","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1210\/jc.2013-3978","article-title":"Vitamin D treatment in primary hyperparathyroidism: a randomized placebo controlled trial","volume":"99","author":"Rolighed","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1001\/archinte.1996.00440110055008","article-title":"Estrogen replacement therapy. A survey of older women\u2019s attitudes","volume":"156","author":"Salamone","year":"1996","journal-title":"Arch Intern Med"},{"key":"B14","unstructured":"The Oxford Levels of Evidence 22011"},{"key":"B15","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/BF02411261","article-title":"Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: observations on regulation of serum calcium","volume":"34","author":"van Breukelen","year":"1982","journal-title":"Calcif Tissue Int"},{"key":"B16","first-page":"480","article-title":"Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism","volume":"110","author":"Jansson","year":"1991","journal-title":"Surgery"},{"key":"B17","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1055\/s-2007-1002158","article-title":"Effect of aminohydroxypropylidene diphosphonate on the bone metabolism of patients with parathyroid adenoma","volume":"25","author":"Ishimura","year":"1993","journal-title":"Horm Metab Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/j.1365-2265.1990.tb00869.x","article-title":"Aminopropylidine diphosphonate (APD) in mild primary hyperparathyroidism: effect on clinical status","volume":"32","author":"Schmidli","year":"1990","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/BF03327373","article-title":"A single bisphosphonate infusion is associated with improved functional capacity in elderly subjects with primary hyperparathyroidism","volume":"15","author":"Ammann","year":"2003","journal-title":"Aging Clin Exp Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1007\/s00268-004-7611-1","article-title":"Biochemical effects from treatment with bisphosphonate and surgery in patients with primary hyperparathyroidism","volume":"28","author":"Jansson","year":"2004","journal-title":"World J Surg"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.jamcollsurg.2007.11.010","article-title":"Hyperparathyroid crisis: use of bisphosphonates as a bridge to parathyroidectomy","volume":"206","author":"Phitayakorn","year":"2008","journal-title":"J Am Coll Surg"},{"key":"B22","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1365-2265.1994.tb03783.x","article-title":"Effect of bisphosphonate therapy and parathyroidectomy on the urinary excretion of galactosylhydroxylysine in primary hyperparathyroidism","volume":"41","author":"LoCascio","year":"1994","journal-title":"Clin Endocrinol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"705","DOI":"10.4158\/EP08178.ORR","article-title":"Alendronate therapy in men with primary hyperparathyroidism","volume":"15","author":"Khan","year":"2009","journal-title":"Endocr Pract"},{"key":"B24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0169-6009(08)80249-8","article-title":"Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget\u2019s disease of bone","volume":"25","author":"Adami","year":"1994","journal-title":"Bone Miner"},{"key":"B25","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1055\/s-0033-1349842","article-title":"Osteoprotegerin, RANKL, and bone turnover in primary hyperparathyroidism: the effect of parathyroidectomy and treatment with alendronate","volume":"45","author":"Szymczak","year":"2013","journal-title":"Horm Metab Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.3275\/9095","article-title":"Comparison of alendronate and raloxifene for the management of primary hyperparathyroidism","volume":"36","author":"Akbaba","year":"2013","journal-title":"J Endocrinol Invest"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1007\/s00198-014-3000-2","article-title":"Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism","volume":"26","author":"Cesareo","year":"2015","journal-title":"Osteoporos Int"},{"key":"B28","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1210\/jc.2002-020890","article-title":"Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism","volume":"88","author":"Chow","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"B29","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/00019616-200111000-00006","article-title":"Alendronate therapy of primary hyperparathyroidism","volume":"11","author":"Hassani","year":"2001","journal-title":"Endocrinologist"},{"key":"B30","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.1210\/jc.2003-030908","article-title":"Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial","volume":"89","author":"Khan","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"B31","first-page":"19","article-title":"Treatment with oral biphosphonates can increase the sensitivity of sestamibi radionuclide imaging in patients with primary hyperparathyroidism","volume":"25","author":"Makras","year":"2005","journal-title":"Int J Clin Pharmacol Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"4482","DOI":"10.1210\/jc.2001-010385","article-title":"Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: a 2-year study","volume":"87","author":"Parker","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"B33","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1359\/jbmr.2001.16.1.113","article-title":"Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism","volume":"16","author":"Rossini","year":"2001","journal-title":"J Bone Miner Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/j.1365-2265.1990.tb00504.x","article-title":"Regulation of calcium-parathyroid hormone feedback in primary hyperparathyroidism: effects of bisphosphonate treatment","volume":"33","author":"Adami","year":"1990","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.7326\/0003-4819-95-1-23","article-title":"Effects of dichloromethylene diphosphonate on serum and urinary calcium in primary hyperparathyroidism","volume":"95","author":"Shane","year":"1981","journal-title":"Ann Intern Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/S0140-6736(80)91496-8","article-title":"Effect of dichloromethylene diphosphonate in Paget\u2019s disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease","volume":"1","author":"Douglas","year":"1980","journal-title":"Lancet"},{"key":"B37","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1136\/bmj.286.6365.587","article-title":"Drug treatment of primary hyperparathyroidism: use of clodronate disodium","volume":"286","author":"Douglas","year":"1983","journal-title":"Br Med J"},{"key":"B38","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/j.1365-2265.2007.03076.x","article-title":"The management of high-risk patients with primary hyperparathyroidism \u2013 minimally invasive parathyroidectomy vs. medical treatment","volume":"68","author":"Fang","year":"2008","journal-title":"Clin Endocrinol"},{"key":"B39","first-page":"S69","article-title":"Clodronate in the medical management of hyperparathyroidism","volume":"8","author":"Hamdy","year":"1987","journal-title":"Bone"},{"key":"B40","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1159\/000048935","article-title":"A strategy for the management of elderly women with primary hyperparathyroidism: a comparison of etidronate therapy with parathyroidectomy","volume":"48","author":"Horiuchi","year":"2002","journal-title":"Gerontology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1002\/j.1552-4604.1977.tb04624.x","article-title":"Metabolic effects of diphosphonate in primary hyperparathyroidism","volume":"17","author":"Kaplan","year":"1977","journal-title":"J Clin Pharmacol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1210\/jcem.77.4.8408454","article-title":"Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate","volume":"77","author":"Reasner","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"B43","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00774-013-0473-6","article-title":"Effect of parathyroidectomy versus risedronate on volumetric bone mineral density and bone geometry at the tibia in postmenopausal women with primary hyperparathyroidism","volume":"32","author":"Tournis","year":"2014","journal-title":"J Bone Miner Metab"},{"key":"B44","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00223-011-9489-x","article-title":"Long-term effects of neridronate and its discontinuation in patients with primary hyperparathyroidism","volume":"89","author":"Rossini","year":"2011","journal-title":"Calcif Tissue Int"},{"key":"B45","doi-asserted-by":"publisher","first-page":"829","DOI":"10.4236\/ijcm.2014.514111","article-title":"Long term outcome of bisphosphonate therapy in patients with primary hyperparathyroidism","volume":"5","author":"Segula","year":"2014","journal-title":"Int J Clin Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00774-005-0680-x","article-title":"Bisphosphonate pretreatment attenuates hungry bone syndrome postoperatively in subjects with primary hyperparathyroidism","volume":"24","author":"Lee","year":"2006","journal-title":"J Bone Miner Metab"},{"key":"B47","doi-asserted-by":"publisher","first-page":"456","DOI":"10.5603\/EP.2014.0063","article-title":"Five-year longitudinal evaluation of mild primary hyperparathyroidism \u2013 medical treatment versus clinical observation","volume":"65","author":"Vera","year":"2014","journal-title":"Endokrynol Pol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"715","DOI":"10.7326\/M15-1232","article-title":"The relationship of parathyroidectomy and bisphosphonates with fracture risk in primary hyperparathyroidism: an observational study","volume":"164","author":"Yeh","year":"2016","journal-title":"Ann Intern Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"66","DOI":"10.4081\/aiua.2015.1.66","article-title":"Use of cinacalcet in nephrolithiasis associated with normocalcemic or hypercalcemic primary hyperparathyroidism: results of a prospective randomized pilot study","volume":"87","author":"Brardi","year":"2015","journal-title":"Arch Ital Urol Androl"},{"key":"B50","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3275\/7970","article-title":"Cinacalcet efficacy in patients with moderately severe primary hyperparathyroidism according to the European Medicine Agency prescription labeling","volume":"35","author":"Cetani","year":"2012","journal-title":"J Endocrinol Invest"},{"key":"B51","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s12020-015-0696-5","article-title":"Cinacalcet therapy in patients affected by primary hyperparathyroidism associated to Multiple Endocrine Neoplasia Syndrome type 1 (MEN1)","volume":"52","author":"Giusti","year":"2016","journal-title":"Endocrine"},{"key":"B52","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1530\/EJE-12-0117","article-title":"MEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly","volume":"167","author":"Filopanti","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s12020-014-0381-0","article-title":"Potential role of cinacalcet hydrochloride in sporadic primary hyperparathyroidism without surgery indication","volume":"49","author":"Marotta","year":"2015","journal-title":"Endocrine"},{"key":"B54","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s12020-011-9459-0","article-title":"Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism","volume":"39","author":"Faggiano","year":"2011","journal-title":"Endocrine"},{"key":"B55","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1097\/SLA.0b013e31824c5252","article-title":"Calcimimetics versus parathyroidectomy for treatment of primary hyperparathyroidism: retrospective chart analysis of a prospective database","volume":"255","author":"Keutgen","year":"2012","journal-title":"Ann Surg"},{"key":"B56","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1530\/EJE-14-0877","article-title":"Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery","volume":"172","author":"Khan","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1177\/2042018813482344","article-title":"Experience with cinacalcet in primary hyperparathyroidism: results after 1 year of treatment","volume":"4","author":"Luque-Fern\u00e1ndez","year":"2013","journal-title":"Ther Adv Endocrinol Metab"},{"key":"B58","doi-asserted-by":"publisher","first-page":"906163","DOI":"10.1155\/2010\/906163","article-title":"Clinical use of cinacalcet in MEN1 hyperparathyroidism","volume":"2010","author":"Moyes","year":"2010","journal-title":"Int J Endocrinol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1210\/jc.2008-2640","article-title":"Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism","volume":"94","author":"Marcocci","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1245\/s10434-011-2065-9","article-title":"Cinacalcet (Sensipar) provides no measurable clinical benefits for patients with primary hyperparathyroidism and may accelerate bone loss with prolonged use","volume":"19","author":"Norman","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1210\/jc.2004-0842","article-title":"Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism","volume":"90","author":"Peacock","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B62","doi-asserted-by":"publisher","first-page":"4860","DOI":"10.1210\/jc.2009-1472","article-title":"Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study","volume":"94","author":"Peacock","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B63","doi-asserted-by":"publisher","first-page":"E9","DOI":"10.1210\/jc.2010-1221","article-title":"Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity","volume":"96","author":"Peacock","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B64","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.metabol.2007.11.014","article-title":"Cinacalcet for the treatment of primary hyperparathyroidism","volume":"57","author":"Sajid-Crockett","year":"2008","journal-title":"Metabolism"},{"key":"B65","doi-asserted-by":"publisher","first-page":"5644","DOI":"10.1210\/jc.2002-021597","article-title":"The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism","volume":"88","author":"Shoback","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"B66","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/cen.12108","article-title":"Cinacalcet in the management of primary hyperparathyroidism: post marketing experience of an Italian multicentre group","volume":"79","author":"Saponaro","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B67","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1530\/EJE-14-0355","article-title":"The PRIMARA study: a prospective, descriptive, observational study to review cinacalcet use in patients with primary hyperparathyroidism in clinical practice","volume":"171","author":"Schwarz","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1016\/0169-6009(92)90863-9","article-title":"Effects of ipriflavone on bone remodeling in primary hyperparathyroidism","volume":"19","author":"Mazzuoli","year":"1992","journal-title":"Bone Miner"},{"key":"B69","unstructured":"Cinacalcet single dose fast test can foresee therapeutic pthresponse in primary hyperparathyroidism (PHP)?\n            De RemigisA\n            VianaleL\n            De RemigisP\n          J Bone Miner Res272012"},{"key":"B70","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1530\/EJE-14-0940","article-title":"No beneficial effects of vitamin D supplementation on muscle function or quality of life in primary hyperparathyroidism: results from a randomized controlled trial","volume":"172","author":"Rolighed","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1530\/EJE-13-0547","article-title":"Primary hyperparathyroidism and metabolic risk factors, impact of parathyroidectomy and vitamin D supplementation, and results of a randomized double-blind study","volume":"169","author":"Norenstedt","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1530\/EJE-08-0901","article-title":"Vitamin D therapy in patients with primary hyperparathyroidism and hypovitaminosis D","volume":"161","author":"Tucci","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1055\/s-2007-1000769","article-title":"Biochemical effects of a calcium supplement in postmenopausal women with primary hyperparathyroidism","volume":"26","author":"Horowitz","year":"1994","journal-title":"Horm Metab Res"},{"key":"B74","first-page":"414","article-title":"Clinical effects of calcimimetics in hyperparathyroidism","volume":"4","author":"Peacock","year":"2004","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"B75","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/BF02546473","article-title":"Effects of a diphosphonate (disodium etidronate: EHDP) on phosphate metabolism in Paget\u2019s disease of bone, primary hyperparathyroidism and type I hypophosphataemic rickets","volume":"21","author":"Walton","year":"1976","journal-title":"Calcif Tissue Res"},{"key":"B76","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40618-015-0423-3","article-title":"Clinical presentation and management of patients with primary hyperparathyroidism of the Swiss Primary Hyperparathyroidism Cohort: a focus on neuro-behavioral and cognitive symptoms","volume":"39","author":"Trombetti","year":"2016","journal-title":"J Endocrinol Invest"},{"key":"B77","first-page":"6","article-title":"Role of bisphosphonates in the medical management of hyperparathyroidism","volume":"26","author":"Neveen","year":"1994","journal-title":"Acta Chir Austriaca"},{"key":"B78","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1136\/postgradmedj-2012-131707","article-title":"Characteristics, management and outcome of primary hyperparathyroidism in South Africa: a single-centre experience","volume":"89","author":"Paruk","year":"2013","journal-title":"Postgrad Med J"},{"key":"B79","first-page":"124","article-title":"Bisphosphonates can reduce bone hunger after parathyroidectomy in patients with primary hyperparathyroidism and osteitis fibrosa cystica","volume":"51","author":"Franca","year":"2011","journal-title":"Rev Bras Reumatol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PloS Med"},{"key":"B81","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.1007\/s00198-016-3715-3","article-title":"Comparative efficacy of parathyroidectomy and active surveillance in patients with mild primary hyperparathyroidism: a systematic review and meta-analysis","volume":"27","author":"Singh Ospina","year":"2016","journal-title":"Osteoporos Int"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fendo.2017.00079\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,8]],"date-time":"2017-05-08T09:08:39Z","timestamp":1494234519000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fendo.2017.00079\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,20]]},"references-count":81,"alternative-id":["10.3389\/fendo.2017.00079"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2017.00079","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,20]]},"article-number":"79"}}